# BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies

Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology drug developer, announced the launch of a new AI-powered module within its RADR(R) platform to predict the efficacy of combination therapies involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis). Backed by a peer-reviewed analysis of 221 clinical trials, the tool enables precise, biomarker-guided design of cancer treatment regimens, reducing development time and cost by up to one-third. The platform guided the design of Lantern’s FDA-cleared Phase 1B/2 trial in triple-negative breast cancer combining LP-184 and olaparib. Lantern is exploring licensing and commercialization opportunities to scale the system across oncology indications.

 To view the full press release, visit https://ibn.fm/NVQqv

 About Lantern Pharma

 Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. The company’s proprietary AI and machine learning platform, RADR(R), leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern has accelerated the development of its growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers. On average, Lantern’s newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $2.5 million per program.

 NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireAustin, Texaswww.BioMedWire.com512.354.7000 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/biomednewsbreaks-lantern-pharma-nasdaq-ltrn-launches-ai-module-to-accelerate-development-of-targeted-cancer-combination-therapies/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/lantern-pharma-launches-ai-module-to-revolutionize-cancer-treatment/bb498a0c08ad3e63b762ab199e5ae356) 

 



[Reddit Post](https://www.reddit.com/r/HealthCareNewsInfo/comments/1m0nhmk/lantern_pharma_launches_ai_module_to/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/257/15/duneL3PS.webp)